Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alumis Inc. (ALMS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.40, with a market capitalisation of $1.19B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.76 to $31.35. This page covers its latest market performance, valuation, price trends and company information.
$1.19B | |
$8.43 | |
$31.35 | |
$2.76 | |
$8.40 | |
115.00 | |
2.23M | |
-- | |
$31.35 | |
$3.76 | |
-- | |
-- |
Alumis Inc. (ALMS) is trading at $8.40 in pre-market trading as of 2026-09-16 08:57:00, down 0.01% ($0.00) from the previous close of $8.40
Pre-market trading shows how investors are pricing ALMS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Alumis Inc. (ALMS) moved from $11.10 to $8.40, representing a decline of 24.33% ($2.70).
The stock traded between $8.31 and $11.60 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3.95 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.8%
ALMS is currently trading at $8.40, placing it 16.8% of the way from its 52-week low of $3.76 to its 52-week high of $31.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 239 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alumis Inc. (ALMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.